Most SUs increase mortality compared with metformin

December 2011
Diabetes Digest;2011, Vol. 10 Issue 4, p235
The article presents a study on the use of metformin and sulphonylureas (SUs) as treatment for people with sulphonylureas (SUs and associated mortality outcomes, in which study reveals that most SU monotheraphy increases mortality and cardiovascular (CV) risk.


Related Articles

  • Sulphonylurea monotherapy: Increased mortality and CV risk when compared with metformin?  // Diabetes Digest;2011, Vol. 10 Issue 4, p235 

    The article discusses the use of sulphonylurea (SU) monotherapy and metformin for people with type 2 diabetes wherein SU increases mortality and cardiovascular (CV) risk compared with metformin.

  • Perspective: General practice. Gadsby, Roger // Diabetes & Primary Care;2013, Vol. 15 Issue 6, p290 

    The author comments on a study which reveals the risks for cardiovascular disease (CVD) associated with the use of the glucose-lowering agent sulphonylurea.

  • Perspective: Prescribing advisors. Newland-Jones, Philip // Diabetes & Primary Care;2013, Vol. 15 Issue 6, p290 

    The author comments on the increased cardiovascular disease risk associated with the use of the glucose-lowering agent sulphonylurea. He believes that formulary developers and prescribing advisors should be aware of the risks of hypoglycaemia prior to prescribing sulphonylureas. He suggests...

  • Metformin as firstline treatment for type 2 diabetes: are we sure? Boussageon, Rémy; Gueyffier, François; Cornu, Catherine // BMJ: British Medical Journal;1/16/2016, Vol. 352 Issue 8040, ph6748 

    The article examines the safety and efficacy of metformin as first line of treatment of type 2 diabetes patients. Topics covered include the methodological flaws in British Prospective Diabetes Study 34 which recommended metformin for glucose lowering treatment, the meta-analysis of randomized...

  • Case Study--Managing newly diagnosed type-2 diabetes. Bostock-Cox, Beverley // Independent Nurse;6/4/2010, p1 

    The article presents a case study of a 58-year old man, Charlie, who underwent an axillary abscess and was diagnosed as a possible candidate for diabetes. Several changes in his lifestyle and dietary habits for reducing risks of cardiovascular diseases and a continuous monitoring routine were...

  • IIEF-5 score correlates with angiopathy in T2D.  // Diabetes Digest;2011, Vol. 10 Issue 4, p216 

    The article offers information on the correlation of 5-item version of the International Index of Erectile Function (IIEF-5) score with angiopathy among men diagnosed with type 2 diabetes (T2D).

  • Intensive intervention only slightly reduces CV risk in T2D.  // Diabetes Digest;2011, Vol. 10 Issue 4, p205 

    The article discusses a study which reveals the impact of intensive treatment in the slight reduction of the cardiovascular (CV) risks in Type I Diabetes (T1D).

  • Metformin Beats Sulfonylurea Drugs at Lowering Mortality among Diabetics.  // Life Extension;Oct2016, p37 

    The article discusses the meta-analysis that found lower risk of dying from cardiovascular disease for diabetics who use metformin compared to those who use sulfonylureas, another class of diabetes drugs, and metformin and sulfonylureas to be more effective at blood glucose reduction.

  • Rosiglitazone CV risk relative to metformin, sulfonylurea.  // Reactions Weekly;7/21/2007, Issue 1161, p5 

    The article discusses research being done on the link between rosiglitazone, metformin, sulfonylurea and cardiovascular (CV) events. The study examined data obtained from the Ingenix Research Database between July 2000 and December 2004 for patients with type 2 diabetes receiving monotherapy...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics